The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations

Lipids in Health and Disease

Volumn 10, Issue , 2011, Pages

  Aung, Lynn Htet Htet ^a   Yin, Rui Xing ^a   Miao, Lin ^a   Hu, Xi Jiang ^a   Yan, Ting Ting ^a   Cao, Xiao Li ^a   Wu, Dong Feng ^a   Li, Qing ^a   Pan, Shang Ling ^a   Wu, Jin Zhen ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN LIKE KEXIN TYPE 9; UNCLASSIFIED DRUG; LIPID; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHINESE; CHOLESTEROL BLOOD LEVEL; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; FEMALE; GEL ELECTROPHORESIS; GENE FREQUENCY; GENOTYPE; HUMAN; LIPID BLOOD LEVEL; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; ASIAN; BLOOD; COMPARATIVE STUDY; GENETIC ASSOCIATION; GENETICS; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; POPULATION GENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; FEMALE; GENETIC ASSOCIATION STUDIES; GENETICS, POPULATION; GENOTYPE; HUMANS; LIPIDS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMORPHISM, SINGLE NUCLEOTIDE; SERINE ENDOPEPTIDASES; YOUNG ADULT;

EID: 78651302317     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-10-5     Document Type: Article

References (67)

1. Serum cholesterol, blood pressure and mortality: implications from a cohort of 361,662 men. MJ Martin SB Hulley WS Browner LH Kuller D Wentworth, Lancet 1986 2 933 6 10.1016/S0140-6736(86)90597-0 2877128
2. Triglycerides: a risk factor for coronary heart disease. J Davignon JS Cohn, Atherosclerosis 1996 124 57 S64 10.1016/0021-9150(96)05858-3 8831917
3. Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health study. W März H Scharnagl K Winkler A Tiran M Nauck BO Boehm BR Winkelmann, Circulation 2004 110 3068 74 15505088
4. Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men and women with premature coronary artery disease. PO Kwiterovich Jr J Coresh HH Smith PS Bachorik CA Derby TA Pearson, Am J Cardiol 1992 69 1015 21 10.1016/0002-9149(92)90856-T 1561971
5. Serum apolipoproteins AI and B and lipoproteins in middle aged men with and without previous myocardial infarction. PN Durrington L Hunt M Ishola J Kane WP Stephens, Br Heart J 1986 56 206 12 10.1136/hrt.56.3.206 3092846
6. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: Assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trail. WE Boden, Am J Cardiol 2000 86 19L 22L 10.1016/S0002-9149(00)01464-8 11374850
7. Interactions between alcohol intake and the polymorphism of rs708272 on serum high-density lipoprotein cholesterol levels in the Guangxi Hei Yi Zhuang population. Y Zhou R Yin Y Deng Y Li J Wu, Alcohol 2008 42 583 91 10.1016/j.alcohol.2008.08.004 18835593
8. Interactions of the apolipoprotein C-III 3238C > G polymorphism and alcohol consumption on serum triglyceride levels. Y Ruixing L Yiyang L Meng L Kela L Xingjiang Z Lin L Wanying W Jinzhen Y Dezhai L Weixiong, Lipids Health Dis 2010 9 86 20716347
9. Association of LIPC -250G > A polymorphism and several environmental factors with serum lipid levels in the Guangxi Bai Ku Yao and Han populations. L Meng Y Ruixing L Yiyang L Xingjiang L Kela L Wanying Z Lin L Weixiong Y Dezhai P Shangling, Lipids Health Dis 2010 9 28 10.1186/1476-511X-9-28 20222961
10. Association of the LIPG 584C > T polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations. WY Liu RX Yin L Zhang XL Cao L Miao DF Wu LH Aung XJ Hu WX Lin DZ Yang, Lipids Health Dis 2010 9 110 10.1186/1476-511X-9-110 20923576
11. Association of methylenetetrahydrofolate reductase C677T polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations. L Zhang RX Yin WY Liu L Miao DF Wu LH Aung XJ Hu XL Cao JZ Wu SL Pan, Lipids Health Dis 2010 9 123 10.1186/1476-511X-9-123 20977771
12. Comparison of demography, diet, lifestyle, and serum lipid levels between the Guangxi Bai Ku Yao and Han populations. Y Ruixing F Qiming Y Dezhai L Shuquan L Weixiong P Shangling W Hai Y Yongzhong H Feng Q Shuming, J Lipid Res 2007 48 2673 81 10.1194/jlr.M700335-JLR200 17890682
13. Hyperlipidaemia and its risk factors in the Guangxi Bai Ku Yao and Han populations. Y Ruixing Y Dezhai L Shuquan C Yuming Y Hanjun F Qiming P Shangling L Weixiong T Jing L Yiyang, Public Health Nutr 2009 12 816 24 10.1017/S1368980008003273 18647432
14. Genetic and environmental influences on serum lipid levels in twins. DA Heller U de Faire NL Pedersen G Dahlén GE McClearn, N Engl J Med 1993 328 1150 6 10.1056/NEJM199304223281603 8455681
15. Multivariate genetic analysis of high density lipoprotein particles. J Steinmetz E Boerwinkle R Gueguen S Visvikis J Henny G Siest, Atherosclerosis 1992 92 219 27 10.1016/0021-9150(92)90281-K 1385955
16. Familial resemblance of plasma lipids, lipoproteins and postheparin lipoprotein and hepatic lipases in the HERITAGE Family Study. L Pérusse T Rice JP Després J Bergeron MA Province J Gagnon AS Leon DC Rao JS Skinner JH Wilmore C Bouchard, Arterioscler Thromb Vasc Biol 1997 17 3263 9 9409321
17. Adenoviral-mediated expression of PCSK9 in mice results in a low-density lipoprotein receptor knockout phenotype. KN Maxwell JL Breslow, Proc Natl Acad Sci USA 2004 101 7100 5 10.1073/pnas.0402133101 15118091
18. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. SW Park YA Moon JD Horton, J Biol Chem 2004 279 50630 8 10.1074/jbc.M410077200 15385538
19. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. S Benjannet D Rhainds R Essalmani J Mayne L Wickham W Jin MC Asselin J Hamelin M Varret D Allard M Trillard M Abifadel A Tebon AD Attie DJ Rader C Boileau L Brissette M Chrétien A Prat NG Seidah, J Biol Chem 2004 279 48865 75 10.1074/jbc.M409699200 15358785
20. Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. F Lalanne G Lambert MJ Amar M Chetiveaux Y Zair AL Jarnoux K Ouguerram J Friburg NG Seidah HB Brewer Jr M Krempf P Costet, J Lipid Res 2005 46 1312 9 10.1194/jlr.M400396- JLR200 15741654
21. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. K Ouguerram M Chetiveaux Y Zair P Costet M Abifadel M Varret C Boileau T Magot M Krempf, Arterioscler Thromb Vasc Biol 2004 24 1448 53 10.1161/01.ATV.0000133684.77013.88 15166014
22. Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia. XM Sun ER Eden I Tosi CK Neuwirth D Wile RP Naoumova AK Soutar, Hum Mol Genet 2005 14 1161 9 10.1093/hmg/ddi128 15772090
23. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. G Lambert AL Jarnoux T Pineau O Pape M Chetiveaux C Laboisse M Krempf P Costet, Endocrinology 2006 147 4985 95 10.1210/en.2006-0098 16794006
24. Proteolytic processing in the secretory pathway. A Zhou G Webb X Zhu DF Steiner, J Biol Chem 1999 274 20745 8 10.1074/jbc.274.30.20745 10409610
25. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. KN Maxwell EA Fisher JL Breslow, Proc Natl Acad Sci USA 2005 102 2069 74 10.1073/pnas.0409736102 15677715
26. The proprotein convertase PCSK9 induces the degradation of LDLR and its closest family members VLDLR and APOER2. S Poirier G Mayer S Benjannet E Bergeron J Marcinkiewicz N Nassoury H Mayer J Nimpf A Prat NG Seidah, J Biol Chem 2008 283 2363 72 10.1074/jbc.M708098200 18039658
27. Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia. KN Maxwell JL Breslow, Curr Opin Lipidol 2005 16 167 72 10.1097/01.mol.0000162321.31925.a3 15767856
28. Binding of PCSK9 to EGFA repeat of LDL receptor decreases receptor recycling and increases degradation. DW Zhang TA Lagace R Garuti Z Zhao M McDonald JD Horton JC Cohen HH Hobbs, J Biol Chem 2007 282 18602 12 10.1074/jbc.M702027200 17452316
29. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. D Cunningham DE Danley KF Geoghegan MC Griffor JL Hawkins TA Subashi AH Varghese MJ Ammirati JS Culp LR Hoth MN Mansour KM McGrath AP Seddon S Shenolikar KJ Stutzman-Engwall LC Warren D Xia X Qiu, Nat Struct Mol Biol 2007 14 413 9 10.1038/nsmb1235 17435765
30. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. NG Seidah S Benjannet L Wickham J Marcinkiewicz SB Jasmin S Stifani A Basak A Prat M Chretien, Proc Natl Acad Sci USA 2003 100 928 33 10.1073/pnas.0335507100 12552133
31. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. NG Seidah S Benjannet L Wickham J Marcinkiewicz SB Jasmin S Stifani A Basak A Prat M Chretien, Proc Natl Acad Sci USA 2003 100 928 33 10.1073/pnas.0335507100 12552133
32. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. M Abifadel M Varret JP Rabès D Allard K Ouguerram M Devillers C Cruaud S Benjannet L Wickham D Erlich A Derré L Villéger M Farnier I Beucler E Bruckert J Chambaz B Chanu JM Lecerf G Luc P Moulin J Weissenbach A Prat M Krempf C Junien NG Seidah C Boileau, Nat Genet 2003 34 154 6 10.1038/ng1161 12730697
33. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. KM Timms S Wagner ME Samuels K Forbey H Goldfine S Jammulapati MH Skolnick PN Hopkins SC Hunt DM Shattuck, Hum Genet 2004 114 349 53 10.1007/s00439-003-1071-9 14727179
34. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. TP Leren, Clin Genet 2004 65 419 22 10.1111/j.0009-9163. 2004.0238.x 15099351
35. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. JC Cohen E Boerwinkle TH Mosley Jr HH Hobbs, N Engl J Med 2006 354 1264 72 10.1056/NEJMoa054013 16554528
36. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. J Cohen A Pertsemlidis IK Kotowski R Graham CK Garcia HH Hobbs, Nat Genet 2005 37 161 5 10.1038/ng1509 15654334
37. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. IK Kotowski A Pertsemlidis A Luke RS Cooper GL Vega JC Cohen HH Hobbs, Am J Hum Genet 2006 78 410 22 10.1086/500615 16465619
38. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. SN Chen CM Ballantyne AM Gotto Jr Y Tan JT Willerson AJ Marian, J Am Coll Cardiol 2005 45 1611 9 10.1016/j.jacc.2005.01.051 15893176
39. The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women. D Evans FU Beil, BMC Med Genet 2006 7 66 10.1186/1471-2350-7-66 16875509
40. Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. GD Norata K Garlaschelli L Grigore S Raselli S Tramontana F Meneghetti R Artali D Noto AB Cefal G Buccianti M Averna AL Catapano, Atherosclerosis 2010 208 177 82 10.1016/j.atherosclerosis.2009.06.023 19619878
41. The PCSK9 gene E670G polymorphism affects low-density lipoprotein cholesterol levels but is not a risk factor for coronary artery disease in ethnic Chinese in Taiwan. LA Hsu MS Teng YL Ko CJ Chang S Wu CL Wang CF Hu, Clin Chem Lab Med 2009 47 154 8 10.1515/CCLM.2009.032 19191720
42. Molecular population genetics of PCSK9: a signature of recent positive selection. K Ding IJ Kullo, Pharmacogenet Genomics 2008 18 169 79 10.1097/FPC.0b013e3282f44d99 18300938
43. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men. M Scartezini C Hubbart RA Whittall JA Cooper AH Neil SE Humphries, Clin Sci (Lond) 2007 113 435 41 10.1042/CS20070150 17550346
44. Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population. E Polisecki I Peter M Robertson AD McMahon I Ford C Packard J Shepherd JW Jukema GJ Blauw RG Westendorp AJ de Craen S Trompet BM Buckley MB Murphy JM Ordovas EJ Schaefer PROSPER Study Group, Atherosclerosis 2008 200 95 101 10.1016/j.atherosclerosis.2007.12.005 18262190
45. Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study. CC Huang M Fornage DM Lloyd-Jones GS Wei E Boerwinkle K Liu, Circ Cardiovasc Genet 2009 2 354 61 10.1161/CIRCGENETICS.108.828467 20031607
46. An epidemiological study of cardiovascular and cardiopulmonary disease risk factors in four populations in the People's Republic of China. Baseline report from the P.R.C.-U.S.A. Collaborative Study. People's Republic of China - United States Cardiovascular and Cardiopulmonary Epidemiology Research Group, Circulation 1992 85 1083 96 1537106
47. Diet, lifestyle, and blood pressure of the middle-aged and elderly in the Guangxi Bai Ku Yao and Han populations. Y Ruixing L Weixiong Y Hanjun Y Dezhai L Shuquan P Shangling F Qiming W Jinzhen G Jianting D Yaju, Am J Hypertens 2008 21 382 7 10.1038/ajh.2008.1 18369357
48. Comparison of hypertension and its risk factors between the Guangxi Bai Ku Yao and Han populations. Y Ruixing P Shangling L Shuquan Y Dezhai L Weixiong F Qiming C Yuming H Yaoheng Z Yijiang L Qinchen, Blood Press 2008 17 306 16 10.1080/08037050802589593 19043819
49. Predictive values of body mass index and waist circumference to risk factors of related diseases in Chinese adult population. Cooperative Meta-analysis Group of China Obesity Task Force, Chin J Epidemiol 2002 23 5 10
50. Mediterranean diet, traditional risk factors and the rate of cardiovascular complications after myocardial infarction. Final report of the Lyon Diet Heart Study. M de Lorgeril P Salen JL Martin I Monjaud J Delaye N Mamelle, Circulation 1999 99 779 85 9989963
51. Effect of maize embryo on delaying aging. W Dong X Ma D Zhang S Yu, Food Sci 2002 23 95 7
52. Dietary fibres: effects on lipid metabolism and mechanisms of action. D Lairon, Eur J Clin Nutr 1996 50 125 33 8654325
53. Long-term treatment of hypercholesterolemia with dietary fiber. DB Hunninghake VT Miller JC LaRosa B Kinosian T Jacobson V Brown WJ Howard DA Edelman RR O'Connor, Am J Med 1994 97 504 8 10.1016/0002-9343(94)90344-1 7985708
54. Meta-analysis of the effects of soy protein intake on serum lipids. JW Anderson BM Johnstone ME Cook-Newell, N Engl J Med 1995 333 276 82 10.1056/NEJM199508033330502 7596371
55. Relation between soy-associated isoflavones and LDL and HDL cholesterol concentrations in humans: a meta-analysis. RM Weggemans EA Trautwein, Eur J Clin Nutr 2003 57 940 6 10.1038/sj.ejcn.1601628 12879088
56. Stronger suppression of plasma cholesterol and enhancement of the fecal excretion of steroids by a buckwheat protein product than by a soy protein isolate in rats fed on a cholesterol-free diet. H Tomotake I Shimaoka J Kayashita F Yokoyama M Nakajoh N Kato, Biosci Biotechnol Biochem 2001 65 1412 4 10.1271/bbb.65.1412 11471745
57. Effect of adlay, buckwheat and barley on lipid metabolism and aorta histopathology in rats fed an obesogenic diet. BK Son JY Kim SS Lee, Ann Nutr Metab 2008 52 181 7 10.1159/000138121 18544971
58. The effect of Ipomoea batatas (Caiapo) on glucose metabolism and serum cholesterol in patients with type 2 diabetes: a randomized study. BH Ludvik K Mahdjoobian W Waldhaeusl A Hofer R Prager A Kautzky-Willer G Pacini, Diabetes Care 2002 25 239 40 10.2337/diacare.25.1.239 11772921
59. Estrogenic effect of yam ingestion in healthy postmenopausal women. WH Wu LY Liu CJ Chung HJ Jou TA Wang, J Am Coll Nutr 2005 24 235 43 16093400
60. Hypolipidemic effect of Telfairia occidentalis (fluted pumpkin) in rats fed a cholesterol-rich diet. OA Adaramoye J Achem OO Akintayo MA Fafunso, J Med Food 2007 10 330 6 10.1089/jmf.2006.213 17651070
61. Cholesterol-induced stimulation of platelet aggregation is prevented by a hempseed-enriched diet. MA Prociuk AL Edel MN Richard NT Gavel BP Ander CM Dupasquier GN Pierce, Can J Physiol Pharmacol 2008 86 153 9 10.1139/Y08-011 18418423
62. Dietary hempseed reduces platelet aggregation. MN Richard R Ganguly SN Steigerwald A Al-Khalifa GN Pierce, J Thromb Haemost 2007 5 424 5 10.1111/j.1538-7836.2007.02327.x 17155962
63. Effect of Canabis Sativa L on serum cholesterol level in rats. L Cen W Qin Y Ye, J Guangxi Med Univ 1984 1 20 2
64. The effect of some foods on serum cholesterol level in rats. W Qin L Cen Y Ye, Acta Nutrimenta Sinica 1986 8 136 40
65. Effects of hempseed and flaxseed oils on the profile of serum lipids, serum total and lipoprotein lipid concentrations and haemostatic factors. US Schwab J Callaway AT Erkkila J Gynther MI Uusitupa T Jarvinen, Eur J Nutr 2006 45 470 7 10.1007/s00394-006-0621-z 17103080
66. Experimental study on the effects of hemp fruit oil on serun lipid levels and lipid peroxidation. HY Ren HG Sun JZ Ma Y Zhang CR Yi MX Wu WL Liu GL Li, Chin J Tradit Med Sci Technol 1997 4 200
67. Lipid-lowering and antiatherosclerotic effects of hemp fruit oil in partridges. HY Ren HG Sun Y Zhang CR Yi MX Wu GL Li WL Liu, Henan Tradit Chin Med 1998 18 294 5